ATOS

Atossa Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website atossatherapeutics.com
Employees(FY) 11
ISIN US04962H5063

Performance

-16.2%

-24.71%

-33.99%

-13.96%

+9.51%

YTD

+32.38%

Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Advanced Technical Analysis

Technical Analysis of ATOS 2024-12-20

The stock's indicators reflect a bearish sentiment, with a Moving Average Score of 10, an Oscillators Score of 36, and an overall Technical Score of 23, indicating a lack of upward momentum and potential weakness in the market. This combination suggests that caution is warranted for investors considering positions in this stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ATOS

Stock Rank

Recent News & Updates

2024-12-19 20:40
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?(Yahoo Finance)
2024-12-12 19:20
Atossa Therapeutics to present poster on Z-endoxifen at SABCS(Yahoo Finance)
2024-12-11 19:15
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium(Globenewswire)
2024-12-10 19:15
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density(Globenewswire)
2024-12-09 20:05
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium(Globenewswire)
2024-12-08 19:15
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research(Globenewswire)
2024-11-20 19:30
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research(Globenewswire)
2024-11-19 19:30
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium(Globenewswire)
2024-11-11 19:30
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-11-04 19:30
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development(Globenewswire)
2024-11-03 17:30
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:(Globenewswire)
2024-10-30 20:15
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer(Globenewswire)
2024-10-27 21:40
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?(Yahoo Finance)
2024-10-20 20:30
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer(Globenewswire)
2024-10-14 19:32
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women(Prnewswire)
2024-10-14 05:08
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-30 20:30
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum(Globenewswire)
2024-09-18 21:40
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?(Yahoo Finance)
2024-09-09 20:30
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer(Globenewswire)
2024-09-02 21:40
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?(Yahoo Finance)
2024-09-02 20:30
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-30 00:00
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice(Yahoo Finance)
2024-08-27 20:30
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen(Globenewswire)
2024-08-20 23:30
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer(Globenewswire)
2024-08-20 20:30
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer(Globenewswire)
2024-08-19 20:30
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations(Globenewswire)
2024-08-11 20:30
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-07-21 20:30
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer(Globenewswire)
2024-07-10 21:40
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?(Yahoo Finance)
2024-07-10 19:00
3 Dirt-Cheap Drug Developers With Blockbuster Potential(Investorplace)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.